
Is regular zzso monitoring useful in clinical practice in multiple sclerosis patients treated with disease zzso therapy zzso zzso My answer is zzso zzso a zzso drug is not by itself a pertinent criterion for requiring a systematic zzso monitoring in zzso zzso Five clinical criteria should be taken into consideration before prescribing regular zzso zzso The clinical form of the disease: zzso monitoring in zzso treated patients, has been demonstrated as useful only in pure zzso zzso zzso Up to now, there is no convincing demonstration of therapeutic efficacy with any zzso drug, neither zzso nor zzso drugs in patients with primary or secondary progressive zzso zzso The duration of the disease, zzso data leading to the concept of a zzso disability progression in zzso emphasizes the importance of treating as early as possible zzso patients in order to stop zzso of new focal zzso zzso zzso In this regard, an annual monitoring for the 5 first years of the disease looks reasonable in order to better personalize the treatment choice among the few approved zzso zzso The duration of the zzso a first zzso assessment at month 6 after initiating a new zzso drug is adequate in order to better distinguish zzso versus no zzso The persistence of zzso at 6 months is a strong indication for considering alternative zzso The disease activity: both criteria, clinical and zzso are needed to recognized very active or aggressive zzso zzso patients, leading to decide a rapid use of zzso treatment zzso The treatment choice: in zzso positive zzso patients treated with zzso the risk of zzso is as high as more than 1 % in those zzso patients that are treated continuously more than 24 zzso A regular zzso monitoring (3 or zzso is recommended in order to detect as early as possible zzso abnormalities suggesting zzso 

